Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

(2019) René-Olivier Casasnovas et al.   LANCET ONCOLOGY

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

(2018) David J. Straus et al.   BLOOD

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

(2017) Peter Borchmann et al.   LANCET

Interim Positron Emission Tomography Response–Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study

(2016) Pier Luigi Zinzani et al.   JOURNAL OF CLINICAL ONCOLOGY

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816

(2016) Oliver W. Press et al.   JOURNAL OF CLINICAL ONCOLOGY

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

(2016) Peter Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hodgkin lymphoma in children and adolescents: improving the therapeutic index

(2015) K. M. Kelly   BLOOD

qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma

(2014) Dirk Hasenclever et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031

(2014) Debra L. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: A children's oncology group report

(2014) Tanya M. Trippett et al.   PEDIATRIC BLOOD & CANCER

Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma

(2013) Paul D. Harker-Murray et al.   PEDIATRIC BLOOD & CANCER

Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

(2012) Leo I. Gordon et al.   JOURNAL OF CLINICAL ONCOLOGY

Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group

(2011) Peter Borchmann et al.   JOURNAL OF CLINICAL ONCOLOGY

BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group

(2010) K. M. Kelly et al.   BLOOD

Consolidation Radiotherapy in Patients With Advanced Hodgkin's Lymphoma: Survival Data From the UKLG LY09 Randomized Controlled Trial (ISRCTN97144519)

(2010) Peter W.M. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study

(2010) Christine Mauz-Körholz et al.   JOURNAL OF CLINICAL ONCOLOGY

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425

(2009) C. L. Schwartz et al.   BLOOD